Abstract. The prostate transglutaminase, TGase-4, is a member of the transglutaminase family and is uniquely expressed in the prostate gland. The function of the protein is largely unknown, although an influence on cell motility and adhesion has been indicated. The present study investigated the impact of the differential expression of TGase-4 in human prostate cancer cells on RON, the hepatocyte growth factorlike/macrophage-stimulating protein (HGF-L/MSP) receptor, mediated cellular functions. Using human prostate cancer cell lines and prostate tissues, we demonstrated that human TGase-4 had a high degree of co-localisation with RON, primarily at the cell periphery and cell-cell adhesion region. High levels of TGase-4 expression in CAHPV10 cells and in PC3 cells engineered to over-express TGase-4 were associated with significantly increased cell motility in response to HGF-L, a clear contrast to wild-type and control cells. Neutralising antibody to RON and rhHGFL/MSP had no further bearing on the increased motility in TGase-4 over-expressing cells, although they had profound effect on the control cells. Akt pathway inhibitor significantly diminished the effect induced by HGF-L in the cells. Finally, over-expression of TGase-4 in prostate cancer cells resulted in autophosphorylation of RON. It is concluded that TGase-4 expression is intrinsically linked to the activation of RON in prostate cancer cells and that this autoactivation of RON contributes to the increased cell motility in TGase-4 expressing cells.
Introduction
Transglutaminases [EC 2.3.2.13 (TGases)] are a family of proteins that catalyse the post-translational modification of proteins by the formation of Â-(Á-glutamyl) lysine isopeptide bonds. One of the unique TGases is the prostate transglutaminase (also known as TGase-4 or TGaseP). TGase-4 is largely confined to the prostate gland (1) (2) (3) . TGases were implicated as contributory to the early suggested concept and role of the tumour microenvironment and tumorigenesis (4) (5) (6) (7) , regulate the adhesion to matrix and migration over matrix (8, 9) . These controversial in vitro reports are reflected by clinical observations that TGase-2 has been shown to be either favorably or inversely correlated with patients outcome (10) .
There is little knowledge on the role of TGase-4 in cancer. Restricted to luminal epithelial cells (with no presence in basal epithelial cells or stromal cells), TGase-4 protein was observed in high-grade prostate intraepithelial neoplasia. TGase-4 was seen at a lower level in prostate cancer compared with normal tissues. Metastatic prostate tumours also showed lost of expression (11) . The expression pattern of TGase-4 has not been found thus far for any other prostate-specific marker (12) . Discovered from a human prostate cDNA library (2), the 679 AA transglutaminase was found to share homology with human endothelial cell TGase (88%) and rat prostate TGase (51%). In a recent study (13) , we found the expression pattern of TGase-4 in cells from different tissue origin is broader than we initially anticipated. Colon cancer, lung cancer and prostate cancer cell lines have varying degrees of expression of the enzyme. This is an interesting observation, as previous studies have used normal human tissue cDNAs (1, 12, 14) . This indicates that the expression of TGase-4 may vary between the normal cells and the more genetic instable cancer cell counterpart. The function of the prostate TGase is far from clear. The rat homologue, rat prostate TGase (or DP1) has been suggested to be involved to some degree in sperm cell motility and immunogenicity (15, 16) and immunoregulation (4, 5) . Our recent study (13) demonstrated that loss of TGase-4 from CAHPV10 cells resulted in the cells being less invasive with or without stimulation by hepatocyte growth factor. Furthermore, TGase-4 has also been shown to influence the interaction between prostate cancer cells and endothelial cells (17) . Together with the report that TGase can be up-regulated by androgen in PC346C, but not in LNCaP cells (despite both being androgen responsive cell lines) (1), this suggests that the enzyme may play a role in the control of invasiveness.
RON belongs to a small receptor-type protein tyrosine kinase family and is the receptor for the HGF-like protein (HGF-L, also known as MSP). RON is comprised of two subunits, joined by disulfide bonds with the ß subunit being the main functional unit of the receptor. Upon stimulation by HGF-L, two main clusters of tyrosine sites on the intracellular domain are activated/phosphorylated, Y1238/Y1239 site -the main catalytic site and Y1353/Y1360 -the main docking site of the RON. Downstream of RON activation are a few signalling pathways which ultimately lead to the specific cellular events, for example, Src/MAPK pathway for the mitogenic effect, PI3-K/Akt pathway for the growth/survival and motility effect elicited by HGF-L/MSP (18, 19) . In cancer, RON is overexpressed in breast cancer, colorectal cancer, lung cancer and kidney cancer (20) (21) (22) . Furthermore, HGF-L has been shown to have an increased expression in breast, lung and pancreatic cancers (21) (22) (23) (24) . So far, only limited information is available on RON and HGF-L expression in prostate cancer, in that the staining of RON total protein in tumour was not different from that in normal tissues.
In an attempt to decipher the molecular and cellular mechanisms underlying the action of TGase-4, we conducted a series of protein interaction by way of immunoprecipitation using proteins from human prostate tissues. One of the interacting proteins with TGase-4 was RON. The present study examined how RON and TGase-4 interplayed in the regulation of cellular functions of prostate cancer cells.
Materials and methods

Materials and cell lines.
Human prostate cancer cells, PC-3 and CAHPV10 were from American Type Cell Collection, Manassas, VI, USA. Fresh frozen prostate tissues were collected from University Hospital of Wales under the approval of local ethics committee and obtained immediately after surgery and stored at -80˚C until use.
Rh-HGF-L/MSP and anti-HGF-L receptor/RON (neutralising and non-neutralising were from R&D Systems. Anti-RON and an anti-phosphoRON were from Santa Cruz Biotechnology Inc. Anti-TGase-4 Pab and Mab, respectively from Covalab, ABCAM, and Abnova. ROCK small inhibitor (Y27632) was from Santa Cruz Biotechnology Inc. PI-3-K inhibitor, Akt inhibitor, JNK inhibitor II, ERK inhibitor II, Met kinase inhibitor, Wiskostatin, JAK-3 inhibitor, Jak-Stat pathway inhibitor, PLC-Á inhibitor and Stat-5 inhibitor were from Calbiochem.
Construction of anti-TGAse-4 hammerhead ribozyme transgenes and TGase-4 expression vector.
Hammerhead ribozymes that specifically target a GTC site of the human prostate TGase-4 (GenBank accession NM_003241) were generated as previously described (13, 25) , using the respective primers (Table I ) and the transgene constructed using a pEF6/V5-His vector (Invitrogen, Paisley, Scotland, UK). The following stably transfected cells were established: TGase-4 knock-down cells (CAHPV10 ΔTGase4 ), plasmid only control cells (CAHPV10 pEFa ), and the wild-type, CAHPV10 wt . Full length human TGase-4 coding region was amplified from a cDNA pool of human prostate tissues using primers listed in Table I . The TGase-4 full length coding product was similarly cloned into the pEF6 vectors. Stably transfected cells were designated as PC3 pEF/His and PC3 TGase4exp , for control transfection and TGase-4 expression, respectively.
RNA preparation, RT-PCR and quantitative analysis of
TGase-4 transcript. The polymerase chain reaction (PCR) was performed using sets of primers, given in Table I . ß-actin was amplified and used as a house-keeping control. The level of the prostate TGase transcripts in the above-prepared cDNA was also determined using a real-time quantitative PCR, based on the Amplifluor™ technology that was modified from that the previously reported (26) . The levels of the transcripts were generated from an internal standard (27) that was simultaneously amplified with the samples.
Electric cell-substrate impedance sensing (ECIS) based cell adhesion assay. Two models of ECIS instrument were used: ECIS9600 for screening and ECIS1600R for modelling. In both systems, 8W10 arrays were used (Applied Biophysics Inc., Troy, NY, USA) (28, 29) . Following treating the array surface with a Cysteine solution, the arrays were incubated with complete medium for 1 h. The same number of prostate cancer cells, PC3 pEF/His , PC3 TGase4exp , or PC3 wt , CAHPV ΔTGase4 , CAHPV pEF/His or CAHPV wt (300,000 per well) were added to each wells. Electric changes were continuously monitored for up to 24 h. In the 9600 system, the monitoring was fixed at 30 Hz. In the 1600R system, two conditions were recorded: 400, 4,000 and 40,000 Hz for screening the nature of changes and 4,000 Hz fix frequency for cell modelling (30) .
Detection of RON/HGFLR activation using Western blotting.
Prostate cancer cells were subject to serum before being treated with either plain medium, rhHGFL/MSP or sodium orthovanadate (10 μM in the presence of 1% H 2 O 2 , as positive control). The proteins were loaded onto 8% SDS-PAGE. Following blotting, the membranes were first blocked by 10% semi-skimmed milk before probing with anti-RON or antiphosphoRON (Tyr1238/1239) antibody. After being processed in enhanced chemiluminescent solution, images were obtained using the LumiDoc imaging system (UniDoc, Cambridge, UK).
Immunofluorescence staining of TGase-4 and the HGF-L receptor, RON in cells and tissues.
Fresh prostate tissues (normal and tumour) were collected immediately after radical prostectomy. Frozen sections of prostate tissues (normal and tumour) were cut at a thickness of 6 μm using a cryostat. Fixed sections were incubated in a blocking solution and probed with the primary antibodies, followed by the secondary FITCand TRITC-conjugated in the presence of Hoechst 33258 at 10 μg/ml (Sigma, St. Louis, MO, USA), separated by extensive washings. The images were documented using Cell Lysis software (Olympus).
Statistical analysis was carried out using Minitab. For normality test Anderson-Darling test and for statistical difference Student's t-test were used.
Results
TGase-4 co-localises with RON in CAHPV10 prostate cancer cells, cells highly expressing TGase-4.
To test if there is a spatial relationship between TGase-4 and RON, we selected CAHPV10 cells, a cell type that was shown to highly express TGase-4 in comparison with other prostate cancer cells. Using dual immunofluorescence staining, a clear co-localisation was seen (Fig. 1A, left) . It is noteworthy that the co-localised TGase-4 and RON are seen at the cell periphery (arrows) and cell-cell adhesion areas (arrowheads), with degree of intracellular staining. The superimposed images have shown that the co-localisations occur more prominently at the cell-cell junction area and cell peripheries. Forced expression of TGase-4 in PC-3 cells (PC3 TGase4exp ) also resulted in degree of co-localisation of TGase-4 and RON, primarily at the cell periphery (Fig. 1A,  arrows) and in the cytoplasm region (arrowheads). CAHPV10 cells showing high level expression of TGase-4, were tranfected with the anti-TGase-4 ribozyme transgene. Cells which had virtually lost the TGase-4 transcript (CAHPV ΔTGase4 ) as the result of the transgene, were obtained.
Similar to the CAHPV, PC3 TGase4exp which now expressed good level of TGase-4 following transfection, also showed co-localised TGase-4 and RON. Co-localisations are seen in both cell-cell contact areas as well as in the cytoplasmic regions (indicated by arrows in the merged image) (Fig. 1A,  right panel) .
Co-localisation of TGase-4 and RON in human prostate
tissues. Using dual immunofluorescence staining of HGFLR/ RON and TGase-4, we attempted to address if the two proteins also co-localised in human prostate tissues. As shown in an example in Fig. 1B , TGase-4 and RON showed a high degree of co-localisation in the tissues at the locations seen with the cells. In addition, TGase-4 proteins were seen in both extracellular matrix and in the cytosol in the tissues.
Forced expression of TGase-4 in PC3 cells increases cell motility, the change is directly affected by RON.
Using cells of which TGase-4 expression was genetically manipulated, we first tested the impact on the cell motility using a Electric Cell Impedance Sensing (ECIS) assay. As shown in Fig. 2 , loss of TGase-4 in CAHPV10 cells by way of ribozyme ( Fig.  2A) and forced expression of TGase-4 in PC-3 cells (Fig. 2B ) resulted in increased in cell motility, as demonstrated by rapid rise of resistance (R) after electric wounding.
To test the impact of RON on TGase-4 mediated cell motility, we used a neutralising antibody to human RON protein on PC-3 cells, which had good level of expression of both RON and its ligand HGF-L. Interestingly, anti-RON blocked the migration of PC-3 control cells after wounding, however, the impact of anti-RON on PC3
TGase4exp cells was very limited (Fig. 2B) . Likewise, we have evidence to show that neutralising anti-RON was able to reduce the cell adhesion to the electrode in PC3-control cells and that PC3
TGase4exp cells had lost this response.
Impact of rhHGFL and anti-RON/HGFLR on the motility of prostate cancer cells.
Using ECIS based cell modelling of cell motility, we showed that recombinant human HGFLfg/MSP significantly increase the motility of control cells (Fig. 2C) . However, PC3
TGase4exp cells, the motility of which was increased, did not shown a significant response to rhHGF-L/MSP (Fig. 2C) . Neutralising anti-RON antibody resulted in a significant reduction of the motility in control cells, but not in PC3 TGase4exp cells.
RON/HGFLR activation by rhHGFL/MSP and TGase-4 overexpression.
Using a phosphor-specific anti-RON antibody, it was shown that rhMSP resulted in the phosphorylation of Table I . Primer and oligo-sequences used in the study.
- 
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RON at the tyrosine in both wild-type and in control cells. It is interesting to note that autophosphorylation of the receptor was seen in PC3 TGase4exp cells, with or without rhHGF-L/MSP (Fig. 3) .
Akt inhibitor had a strong inhibitory effect on MSP-induced motility.
A panel of small inhibitors to certain key pathways downstream of MSP and RON. Akt inhibitor showed a significant effect on MSP-induced migration both in PC-3 control and PC3
TGase4exp cells (Fig. 4) .
Discussion
The present study is the first to demonstrate that TGase-4, a prostate-specific transglutaminase, acted in orchestration with the HGF-L/MSP receptor RON in enhancing the motility of prostate cancer cells. The study further demonstrated that the TGase-4 induced increase in cell motility is independent of the presence of the RON ligand, HGFL/MSP. The transglutaminase family has been indicated in the regulation of cell motility and cell-matrix adhesion. Recently, we have shown that knocking down the expression of TGase-4 from a human prostate cancer cell lines, CAHPV which naturally expressed TGase-4, resulted in less motility and adhesive cells (13) , an observation leading to suggestion that TGase-4 is also a motility regulator in prostate cancer cells. Motility of cells is regulated by a number of extracellular regulators. It has been well documented that HGF/SF acts via its receptor, cMET, and contributed to the aggressive nature of cancer cells. The present study was the direct result of a proteomic based study in our laboratory in which we found that RON is one of the small number of proteins interacting with TGase-4. In the present study, the spatial co-localisation between TGase-4 and RON has been confirmed in both prostate cancer cells and in prostate tissues. This is important when considering the potential impact of TGase-4 expression on RON activation and on HGFL/MSP-induced cell motility in prostate cancer cells. enabled the cells to have auto-activated RON, which in turn elicits the activation mechanism for cell motility. HGFL/MSP-induced motility in cells is known to be mediated by a number of key pathways, including Akt and PI3K pathways. The present study has shown that Akt is probably more actively involved in the action as the small inhibitor significantly blocked the action of HGFL/MSP in both PC3 control and PC3
TGase-4exp cells. The observations reported here have important implications to prostate cancer. Over-expression of HGF-L/MSP and its receptor RON have been reported in a few human solid tumours, including pancreatic cancer, breast cancer, thyroid and lung cancer. No large scale study is presently available with regard to the expression pattern of the cytokine and receptor in prostate cancer. In a recent study with small number of prostate tumours (n=40), 10% of the prostate tumours were found to over-express the RON protein. Here, the limited information has shown the presence of RON in prostate cancer cell lines that can be activated by HGF-L/MSP and staining of RON in prostate epithelial cells and cancer cells. Clearly, a large scale study is necessary in order to establish the expression pattern and relationship with tumour development and progression in prostate cancer.
In conclusion, TGase-4 in prostate cancer cells is colocalised with the HGF-L/MSP receptor RON. When overexpressed, TGase-4 prostate cancer cells showed an enhanced response to HGF-L/MSP as demonstrated by their increased cell motility. This response appears to be Akt-dependent. These observations suggest that: i) TGase-4 and HGFL/MSP may have a synergistic effect toward initiating the aggressive behaviour of prostate cancer cells and ii) targeting both RON and TGase-4 may be a plausible approach for therapeutic intervention in prostate cancer.
